We can’t show the full text here under this license. Use the link below to read it at the source.
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium‐glucose cotransporter 2 inhibitors vs dipeptidyl peptidase‐4 inhibitors in Japan: A real‐world administrative database analysis
Healthcare use and costs in Japanese type 2 diabetes patients starting SGLT2 inhibitors compared to DPP-4 inhibitors
AI simplified
Abstract
Patients receiving an SGLT2 inhibitor had lower healthcare resource utilization and costs compared to those receiving a DPP4 inhibitor.
- SGLT2 inhibitor patients experienced significantly fewer hospitalizations and outpatient visits per person per month.
- Lengths of hospital stays were shorter for patients on SGLT2 inhibitors compared to those on DPP4 inhibitors.
- Overall healthcare costs per person per month were generally lower for SGLT2 inhibitor patients.
- Similar trends in healthcare resource utilization and costs were noted in patients with a higher body mass index, but not in those with a lower body mass index.
AI simplified
Key numbers
0.0179
Lower Hospitalizations
Mean number of hospitalizations per person per month for
$364.2
Lower Overall Healthcare Costs
Mean all-cause overall healthcare costs per person per month for
$420.3
Higher Overall Healthcare Costs for
Mean all-cause overall healthcare costs per person per month for